Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2901-2910

  Zhang, Hong ^a   Zhang, Fu Ming ^a   Yan, Shi Jun ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

HPLC; Material phase analysis; Pharmacokinetics; Release profile; Solid lipid nanoparticles; Sorafenib

Indexed keywords

SOLID LIPID NANOPARTICLE; SORAFENIB;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; ENCAPSULATION; EXPERIMENTAL RABBIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; ZETA POTENTIAL;

ANIMALS; BENZENESULFONATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY ACIDS; FEMALE; FREEZE DRYING; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; POWDERS; PYRIDINES; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 84870377063     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32415     Document Type: Article

References (18)

1. Wilhelm SM, Carter C, Tang L, etal. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Can Res. 2004;64(19):7099-7109.
2. Wilhelm S, Carter C, Lynch M, etal. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835-844.
3. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008;49(12):2246-2255.
4. Ravandi F, Cortes JE, Jone D, etal. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11):1856-1862.
5. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006;57(5): 685-692.
6. Li YC, Dong L, Jia A, Chang XM, Xue H. Preparation of solid lipid nanoparticles loaded with traditional Chinese medicine by high-pressure homogenization. South Med Univ. 2006;26(5):541-544.
7. Chen H, Chang X, Du D, etal. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release. 2006;110(2): 296-306.
8. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328(2):191-195.
9. Blanchet B, Billemont B, Cramard J, etal. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49(4):1109-1114.
10. Afify S, Rapp UR, Hogger P. Validation of a liquid chromatography assay for quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;809(1):99-103.
11. Service RF. Nanomaterials show signs of toxicity. Science. 2003; 300(5617):243.
12. Handy RD, Henry TB, Scown TM, Johnston BD, Tyler CR. Manufactured nanoparticles: their uptake and effects on fish-a mechanistic analysis. Ecotoxicology. 2008;17(5):396-409.
13. Chen JF, Zhang DR, Zhang XS, Xing J. Preparation and material phase analysis of solid lipid nanoparticles loading matrine. J Chin Pharm. 2005;36(4):214-217.
14. Liu J, Gong T, Wang CG, Zhong Z, Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int J Pharm. 2007; 340(1-2):153-162.
15. Zhu SS. New Formulation of Drug. Beijing, China: Chemical Industry Press; 2003:435-436.
16. Kurihara A, Shibayama Y, Mizota A, etal. Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice. Pharm Res. 1996;13(2):305-310.
17. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1): 1-12.
18. Qin SK, Gong XL. Progress on sorafenib therapy for primary hepatic carcinoma. Chin Clin Oncol. 2008;13(12):1057-1068.